MC2 and Almirall clear crucial obstacle to psoriasis treatment in Europe

Psoriasis cream Wynzora has safely traversed the decentralized procedure route to approval in Europe, which paves the way for individual national health authorities to vouch for the treatment.

Photo: MC2 Therapeutics / PR

Danish company MC Therapeutics' psoriasis cream Wynzora has cleared another obstacle on the way to the EU markets.

MC2 and its partner, dermatology company Almirall, announce in a press release that Wynzora has successfully completed the decentralized procedure.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs